Introduction
Human tuberculosis (TB) is primarily caused by Mycobacterium
tuberculosis. Pulmonary disease occurs in 70-90% of the patients being
the most commonly affected sites. The standard therapeutic regimen for
TB as recommended by World Health Organization (WHO), consists of two
months of the intensive phase, and four months of the continuation
phase. The intensive-phase drugs include isoniazid (H) 5 mg/kg, rifampin
(R) 10 mg/kg, ethambutol (E) 15 mg/kg, and pyrazinamide (Z) 25 mg/kg.
Then isoniazid and rifampin are continued for the next four months. In
the cases of resistance to isoniazid, treatment with a combination of
rifampin, ethambutol, pyrazinamide, and a quinolone antibiotic such as
levofloxacin (Lfx) is performed for a total of six months [1-3].
Drug-induced hepatitis is the most well-known complication of anti-TB
treatment. Other adverse events include anorexia, vomiting, abdominal
pain, peripheral neuropathy, thrombocytopenia, renal reactions, and skin
rashes [4]. Here, we reported a rare complication of levofloxacin
which was used as a second-line agent for TB treatment.